Daniel D. Von Hoff

Daniel D. Von Hoff, M.D., is a Distinguished Professor at the Translational Genomics Research Institute (TGen) and City of Hope, with a concurrent role as Professor of Medicine at the Mayo Clinic. His research focuses on the development of novel anticancer agents, particularly for pancreatic cancer, and spans over five decades.

• Clinical Genomics and Therapeutics Division, TGen
• Department of Medical Oncology and Therapeutic Research, City of Hope
• Professor of Medicine, Mayo Clinic

Dr. Von Hoff has pioneered the development of numerous FDA-approved drugs for breast, lung, colon, prostate, pancreas, skin cancers, and leukemia, including gemcitabine, paclitaxel, and vismodegib. His clinical trials have led to three of the four FDA approvals for advanced pancreatic cancer treatments.

Scientific awards and recognitions include:

• David A. Karnofsky Memorial Award (2010)
• AACR Distinguished Public Service Award
• AACR Named Lectureship
• Columbia University Gold Medal
• Arizona Historymaker 2023
• Fellowships: F.A.C.P., FASCO, FAACR

He is a founder of ILEX™ Oncology, Inc., and has served as Editor Emeritus of Investigational New Drugs and past Editor-in-Chief of Molecular Cancer Therapeutics. His mentorship of medical students, oncology fellows, and researchers has influenced thousands through educational workshops.